InFlectis BioScience Completes Enrollment of Its Phase 2 Trial of IFB-088 for the Treatment of Amyotrophic Lateral Sclerosis; Anticipates Initial Results Later This Year
2024-01-31
临床2期
Nantes, France--(News - January 31, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2 clinical trial of IFB-088 (INN: icerguastat), a novel investigational treatment of Amyotrophic Lateral Sclerosis (ALS).
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
InFlectis completed enrollment in its Phase 2 clinical trial of IFB-088 in ALS.
IFB-088 is capable of crossing the blood-brain barrier and believed to act by selectively inhibiting a biomolecular switch to give cells additional time to repair or eliminate mis-folded proteins.
Initial findings to be reported as early as the end of 2024.
Click image above to view full announcement.
About InFlectis BioScience
InFlectis is a French-based drug discovery company developing first-in-class therapies for neuromuscular diseases. We are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS and CMT, a rare and progressive hereditary nerve condition.
Contacts:
Philippe Gu'edat
philippeguedat@inflectisbioscience.com
Source: Inflectis
To view the source version of this press release, please visit
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。